1-[(5-chloro-benzo[b]thiophen-3-yl)methyl]-2H-indole-2,3-dione | 445455-64-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-[(5-chloro-benzo[b]thiophen-3-yl)methyl]-2H-indole-2,3-dione
• 英文别名: 1-[(5-chloro-1-benzothien-3-yl)methyl]-2H-indole-2,3-dione；1-[(5-chloro-1-benzothiophen-3-yl)methyl]indole-2,3-dione
• CAS: 445455-64-1
• 化学式: C₁₇H₁₀ClNO₂S
• 分子量: 327.791
• InChiKey: YAFMLULIFQLJRJ-UHFFFAOYSA-N

物化性质

• 沸点：
  533.5±60.0 °C(Predicted)
• 密度：
  1.514±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  65.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(5-chloro-benzo[b]thiophen-3-yl)methyl]-2H-indole-2,3-dione 、 间氨基三氟甲苯 在 crude material 、 乙酸乙酯 、 正己烷 作用下， 反应 2.0h， 以giving the desired product as a yellow solid (13 mg, 0.030 mmol, 18%)的产率得到1-[(5-chloro-benzo[b]thiophen-3-yl)methyl]-3-{[3-(trifluoromethyl)phenyl]imino}-1,3-dihydro-2H-indol-2-one
  参考文献：
  名称：

  Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods

  摘要：

  本发明涉及对GALR3受体具有拮抗作用的吲哚酮衍生物。本发明提供一种药物组合物，包括本发明化合物的治疗有效量和药学上可接受的载体。本发明还提供了一种药物组合物，由本发明化合物的治疗有效量和药学上可接受的载体组合制成。本发明还提供了一种制备药物组合物的方法，包括将本发明化合物的治疗有效量和药学上可接受的载体组合。

  公开号：

  US20040102507A1
• 作为产物：
  描述：

  3-溴甲基-5-氯苯并噻吩 在 sodium hydride 作用下， 以 1,4-二氧六环 为溶剂， 反应 16.08h， 以45%的产率得到1-[(5-chloro-benzo[b]thiophen-3-yl)methyl]-2H-indole-2,3-dione
  参考文献：
  名称：

  WO2008/2946

  摘要：

  公开号：

文献信息

• Discovery of natural product-like spirooxindole derivatives as highly potent and selective LSD1/KDM1A inhibitors for AML treatment
  作者：Chao Yang、Yuan Fang、Xiang Luo、Dehong Teng、Zhongqiu Liu、Yingtang Zhou、Guochao Liao

  DOI：10.1016/j.bioorg.2022.105596

  日期：2022.3

  natural LSD1 inhibitor higenamine, we herein performed further structure-based design, synthesis, and extensive structure–activity relationship (SAR) studies, affording structurally new spirooxindole derivatives. Particularly, FY-56 was identified to be a highly potent LSD1 inhibitor (IC50 = 42 nM) and showed high selectivity over monoamine oxidases (MAO-A/B). Mechanistic studies showed that FY-56 moderately

  组蛋白赖氨酸特异性去甲基化酶 1 (LSD1) 是一种很有前途的癌症治疗新靶点。在发现天然 LSD1 抑制剂去甲素后，我们在此进行了进一步的基于结构的设计、合成和广泛的构效关系 (SAR) 研究，提供了结构上新的螺氧吲哚衍生物。特别是，FY-56 被鉴定为一种高效的 LSD1 抑制剂（IC 50 = 42 nM) 并显示出对单胺氧化酶 (MAO-A/B) 的高选择性。机制研究表明，FY-56 适度抑制白血病细胞的增殖和克隆形成，诱导 H3K4me1/2 积累和 p53 活化，并降低转录因子 HOXA9 和 MEIS1 的 mRNA 水平。同时，FY-56 诱导 MOLM-13 和 MV4-11 细胞的分化，伴随着分化巨噬细胞和单核细胞特征性标志物的百分比增加。进一步的体内研究表明，FY-56 明显降低 CD45 + /CD33 +的比例外周血和脾脏中的白细胞，显着延长小鼠的存活率。总的来说，FY-56
• Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
  申请人：——

  公开号：US20030078271A1

  公开（公告）日：2003-04-24

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性GAL3受体拮抗剂。该发明提供了一种包含该发明化合物的治疗有效量和药用载体的药物组合物。该发明还提供了通过结合该发明化合物的治疗有效量和药用载体制备的药物组合物。该发明进一步提供了一种制备药物组合物的方法，包括结合该发明化合物的治疗有效量和药用载体。该发明还提供了一种治疗患有抑郁症和/或焦虑症的受试者的方法，包括向受试者施用足以治疗受试者抑郁症和/或焦虑症的该发明化合物的量。该发明还提供了一种治疗受试者抑郁症和/或焦虑症的方法，包括向受试者施用包含药用载体和治疗有效量GAL3受体拮抗剂的组合物。
• GAL3 antagonists for the treatment of neuropathic pain
  申请人：——

  公开号：US20040092570A1

  公开（公告）日：2004-05-13

  This invention is directed to pyrimidine and indolone derivatives which are selective antagonists for the GAL3 receptor and are useful for the treatment of neuropathic pain and other abnormalities. This invention also provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's abnormality. This invention also provides a method of treating an abnormality in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist.

  这项发明涉及嘧啶和吲哚酮衍生物，它们是选择性的GAL3受体拮抗剂，可用于治疗神经病痛和其他异常。这项发明还提供了一种治疗患有异常的受试者的方法，包括向受试者投予本发明中的化合物的有效剂量以治疗受试者的异常。这项发明还提供了一种治疗受试者异常的方法，包括向受试者投予包含药用载体和治疗有效量的GAL3受体拮抗剂的组合物。
• Indolone compounds useful to treat cognitive impairment
  申请人：Blackburn P. Thomas

  公开号：US20070135509A1

  公开（公告）日：2007-06-14

  This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.

  这项发明提供了一种治疗患有认知障碍或认知障碍的受试者的方法，包括向受试者施用一定量的吲哚酮化合物，以有效治疗受试者的认知障碍或障碍。
• Indolone Compounds Useful To Treat Cognitive Impairment
  申请人：Blackburn P. Thomas

  公开号：US20070135510A1

  公开（公告）日：2007-06-14

  This invention provides a method of treating a subject suffering from a cognitive impairment or a cognitive disorder which comprises administering to the subject an amount of an indolone compound effective to treat the subject's cognitive impairment or disorder.

  该发明提供了一种治疗患认知障碍或认知障碍的受试者的方法，包括向受试者施用有效治疗受试者认知障碍或障碍的吲哚酮化合物的剂量。